Combination therapy targeting hypoxia inducible factor-α ( HIF-1 α) and Tissue Factor (TF) by the mTOR inhibitor Rapamycin and the histone deacetylase inhibitor LBH589

被引：0
|
作者：
Verheul, Henk M. W.
Qian, David Z.
Van Erp, Karen
Salumbides, Brenda
Sanni, Tolib
Atadja, Peter
Pili, Roberto
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Novartis Inst Biomed Res, E Hanover, NJ USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of pan-histone deacetylase inhibitor panobinostat (LBH589) on CXCR4 levels and signaling and on anti-leukemia activity in combination with CXCR4 antagonists
    Jillella, A. P.
    Mandawat, A.
    Fiskus, W.
    Rao, R.
    Wang, Z.
    Wang, Y.
    Atadja, P.
    Fujii, N.
    Peiper, S.
    Bhalla, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Expression of hypoxia inducible factor 1α (HIF-1α) in the progression to oesophageal adenocarcinoma:: A key target for therapy
    Teratani, Naoki
    Nicholson, Anna M.
    Atherfold, Paul A.
    Milicic, Anita
    Jankowski, Janusz A.
    GASTROENTEROLOGY, 2008, 134 (04) : A441 - A441
  • [33] Hypoxia-Inducible Factor-1 (HIF-1)-Active Cells as a Target for Cancer Therapy
    Kizaka-Kondoh, Shinae
    Kuchimaru, Takahiro
    Kadonosono, Tetsuya
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (04) : 440 - 445
  • [34] Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy
    Hiroaki Ikeda
    Hideaki Kakeya
    The Journal of Antibiotics, 2021, 74 : 687 - 695
  • [35] Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy
    Ikeda, Hiroaki
    Kakeya, Hideaki
    JOURNAL OF ANTIBIOTICS, 2021, 74 (10): : 687 - 695
  • [36] Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor EIF4E Activation in Diffuse Large B-Cell Lymphoma
    Gupta, Mamta
    Ansell, Stephen M.
    Novak, Anne J.
    Witzig, Thomas E.
    BLOOD, 2008, 112 (11) : 226 - 226
  • [37] Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
    George, P
    Bali, P
    Annavarapu, S
    Scuto, A
    Fiskus, W
    Guo, F
    Sigua, C
    Sondarva, G
    Moscinski, L
    Atadja, P
    Bhalla, K
    BLOOD, 2005, 105 (04) : 1768 - 1776
  • [38] Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
    Zhou, Yinghong
    Dong, Xiaofeng
    Xiu, Peng
    Wang, Xin
    Yang, Jianrong
    Li, Lei
    Li, Zhongchao
    Sun, Pengfei
    Shi, Xuetao
    Zhong, Jingtao
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2020, 2020
  • [39] Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation
    Qannita, Reem A.
    Alalami, Ayah I.
    Harb, Amani A.
    Aleidi, Shereen M.
    Taneera, Jalal
    Abu-Gharbieh, Eman
    El-Huneidi, Waseem
    Saleh, Mohamed A.
    Alzoubi, Karem H.
    Semreen, Mohammad H.
    Hudaib, Mohammad
    Bustanji, Yasser
    PHARMACEUTICALS, 2024, 17 (02)
  • [40] Discovery of potent hypoxia-inducible factor-1α (HIF-1α) degraders by proteolysis targeting chimera (PROTAC)
    Li, Yuying
    Zhu, Ruixue
    He, Xuelian
    Song, Yanjia
    Fan, Ting
    Ma, Junhui
    Xiang, Guangya
    Ma, Xiang
    BIOORGANIC CHEMISTRY, 2024, 153
12345